Biosimilar Regulations MCQs With Answer

Biosimilar Regulations MCQs With Answer

This quiz compilation is designed for M.Pharm students studying MIP 104T – Intellectual Property Rights, focusing on regulatory principles for biosimilars. It covers core concepts such as definitions, evidence requirements (analytical, preclinical and clinical), extrapolation of indications, interchangeability, naming, pharmacovigilance, and jurisdictional differences (FDA, EMA, WHO, CDSCO). Questions emphasize regulatory strategy, dossier expectations, and post‑approval obligations, deepening understanding beyond surface-level facts. Use these MCQs to test knowledge, prepare for exams, and reinforce application of guidelines when assessing biosimilar development, approval pathways, and risk‑management requirements in different regulatory frameworks.

Q1. What is the most accurate definition of a biosimilar?

• A new biologic with a completely different structure and mechanism compared to the originator
• A biologic product that is identical in every chemical detail to the reference product
• A biologic product highly similar to a licensed reference product, with no clinically meaningful differences in safety, purity, and potency
• A small molecule generic version of a biologic drug

Correct Answer: A biologic product highly similar to a licensed reference product, with no clinically meaningful differences in safety, purity, and potency

Q2. Which type of evidence typically provides the primary foundation for establishing biosimilarity?

• Randomized phase III clinical trials comparing efficacy across all indications
• Extensive head‑to‑head analytical characterization of quality attributes
• Patent landscape and freedom‑to‑operate analysis
• Marketing and commercial data from the innovator

Correct Answer: Extensive head‑to‑head analytical characterization of quality attributes

Q3. Which regulatory authority generally does NOT make a formal interchangeability designation for biosimilars, leaving substitution policy to national or regional authorities?

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• World Health Organization (WHO)
• Central Drugs Standard Control Organization (CDSCO), India

Correct Answer: European Medicines Agency (EMA)

Q4. For the FDA to grant an interchangeability designation, what additional evidence is specifically required beyond demonstrating biosimilarity?

• Only in vitro analytical data is required for interchangeability
• Evidence from switching studies showing that alternating or switching between the biosimilar and reference product does not increase risk or reduce efficacy
• A marketing exclusivity period of ten years must be waived
• An identical non‑proprietary name without any suffix

Correct Answer: Evidence from switching studies showing that alternating or switching between the biosimilar and reference product does not increase risk or reduce efficacy

Q5. Which of the following is a valid scientific justification for extrapolating indications from the reference product to a biosimilar?

• Different mechanism of action in the extrapolated indication but no clinical data
• Demonstrated similarity in mechanism of action, receptor binding, PK/PD, and comparable immunogenicity risk across indications
• Lower manufacturing cost and improved marketing strategy
• Approval in any other non‑related region regardless of scientific bridging

Correct Answer: Demonstrated similarity in mechanism of action, receptor binding, PK/PD, and comparable immunogenicity risk across indications

Q6. Which WHO document provides globally recognized principles for evaluating similar biotherapeutic products?

• WHO Guidelines on the Evaluation of Similar Biotherapeutic Products
• WHO Pharmaceutical Marketing Guidelines
• WHO Manual on Generic Small Molecules
• WHO Data Exclusivity Code

Correct Answer: WHO Guidelines on the Evaluation of Similar Biotherapeutic Products

Q7. What is the regulatory purpose of data exclusivity in the context of biologics?

• To block any follow‑on product approvals permanently
• To protect the originator’s clinical and non‑clinical trial data from reliance by regulators for a defined period, delaying approval of biosimilars
• To extend the patent term automatically
• To permit automatic interchangeability of biosimilars after market entry

Correct Answer: To protect the originator’s clinical and non‑clinical trial data from reliance by regulators for a defined period, delaying approval of biosimilars

Q8. Which naming convention did the U.S. FDA adopt for biologic products including biosimilars?

• Use of the same INN for all products with no distinguishing elements
• Assignment of a non‑meaningful, FDA‑designated four‑letter suffix appended to the nonproprietary name
• Use of the country code as a suffix
• Unique trade names only, with no INN allowed

Correct Answer: Assignment of a non‑meaningful, FDA‑designated four‑letter suffix appended to the nonproprietary name

Q9. What does the term “biobetter” generally refer to?

• A biosimilar that is exactly identical to the reference biologic
• A biologic engineered to improve one or more clinical attributes compared with the reference product (e.g., efficacy, safety, dosing frequency)
• A generic small molecule equivalent of a biologic
• An originator biologic nearing patent expiry

Correct Answer: A biologic engineered to improve one or more clinical attributes compared with the reference product (e.g., efficacy, safety, dosing frequency)

Q10. After approval, which of the following is a primary post‑marketing regulatory requirement for biosimilars?

• No post‑marketing activity is required once approved
• Enhanced pharmacovigilance and a risk management plan including immunogenicity surveillance
• Immediate interchangeability with all other biologics without monitoring
• Annual renewal of the biosimilarity analytical package only

Correct Answer: Enhanced pharmacovigilance and a risk management plan including immunogenicity surveillance

Q11. When selecting a reference product for a biosimilar dossier, regulators typically require that the reference be:

• A biologic product marketed in any country regardless of licensure status
• A licensed reference product from the same regulatory jurisdiction or justified bridging data if using a foreign‑sourced reference
• Any non‑biologic comparator with a similar therapeutic indication
• The developer’s own earlier biosimilar candidate

Correct Answer: A licensed reference product from the same regulatory jurisdiction or justified bridging data if using a foreign‑sourced reference

Q12. How does “comparability” (used for manufacturing changes of a biologic) differ conceptually from “biosimilarity” between products of different manufacturers?

• Comparability addresses changes within the same manufacturer’s product lifecycle; biosimilarity addresses similarity between products from different manufacturers
• They are interchangeable terms with identical regulatory meaning
• Comparability requires full clinical trials, biosimilarity does not require any data
• Comparability is only concerned with pricing and market access

Correct Answer: Comparability addresses changes within the same manufacturer’s product lifecycle; biosimilarity addresses similarity between products from different manufacturers

Q13. Which immunogenicity assessment is most relevant when evaluating a biosimilar?

• Measurement of anti‑drug antibody incidence and characterization including neutralizing antibodies and clinical impact
• Only measuring total serum protein concentration
• Tracking consumer complaints about packaging
• Assessing the cost‑effectiveness of immunization programs

Correct Answer: Measurement of anti‑drug antibody incidence and characterization including neutralizing antibodies and clinical impact

Q14. The CDSCO (India) guideline for similar biologics recommends which overall development approach?

• A one‑size‑fits‑all strategy consisting solely of clinical efficacy trials for every product
• A stepwise approach including extensive analytical characterization, non‑clinical studies as needed, and clinical studies to confirm similarity
• Waiving all clinical and analytical studies if the product is cheaper
• Immediate approval upon submission of manufacturing details only

Correct Answer: A stepwise approach including extensive analytical characterization, non‑clinical studies as needed, and clinical studies to confirm similarity

Q15. In the United States regulatory framework, biosimilars are licensed under which statutory pathway?

• New Drug Application (NDA)
• Biologics License Application under section 351(k) of the Public Health Service Act (351(k) BLA)
• Abbreviated New Drug Application (ANDA)
• 505(b)(2) application for small molecules

Correct Answer: Biologics License Application under section 351(k) of the Public Health Service Act (351(k) BLA)

Q16. Which scenario would most likely prevent approval of extrapolation to an additional indication for a biosimilar?

• Analytical similarity across critical quality attributes and identical mechanisms of action for all indications
• A distinct mechanism of action or target in the extrapolated indication that has not been scientifically bridged
• Minor differences in glycosylation that do not affect receptor binding
• Comparable PK/PD across studied indications

Correct Answer: A distinct mechanism of action or target in the extrapolated indication that has not been scientifically bridged

Q17. If the FDA designates a biosimilar as interchangeable, what practical effect does this have with respect to pharmacy substitution?

• Automatic nation‑wide substitution is mandated regardless of state law
• Interchangeability allows substitution at the pharmacy level subject to applicable state pharmacy laws and regulations
• The product is banned from substitution under any circumstance
• It requires prescriber approval in all cases and prohibits pharmacist substitution

Correct Answer: Interchangeability allows substitution at the pharmacy level subject to applicable state pharmacy laws and regulations

Q18. What is the primary aim of detailed analytical similarity studies when comparing a biosimilar to its reference product?

• To establish the biosimilar’s market price
• To detect differences in critical quality attributes that could affect safety or efficacy and to justify reduced clinical testing
• To determine packaging aesthetics and patient preference
• To replace the need for any clinical immunogenicity testing

Correct Answer: To detect differences in critical quality attributes that could affect safety or efficacy and to justify reduced clinical testing

Q19. Which practice improves patient traceability for biologics and biosimilars in pharmacovigilance?

• Recording only the INN in all prescriptions without brand or batch information
• Recording brand name and batch number along with the INN to allow identification of the exact product and batch
• Eliminating batch numbering for faster distribution
• Using pharmacy loyalty card data as the sole traceability source

Correct Answer: Recording brand name and batch number along with the INN to allow identification of the exact product and batch

Q20. What study design is most appropriate to satisfy regulatory expectations for interchangeability switching assessments?

• Single‑arm open‑label observational study with no switching
• Randomized, multiple‑switch clinical study comparing alternating sequences of biosimilar and reference product to continuous reference product use
• In vitro comparability only, with no human data
• Cross‑sectional survey of physician opinions

Correct Answer: Randomized, multiple‑switch clinical study comparing alternating sequences of biosimilar and reference product to continuous reference product use

Download